Answers are grounded in this paper and cite their sources.
Background: Endothelial dysfunction, and cardiovascular (CV) morbidity and mortality have been documented in patients with ankylosing spondylitis (AS). Endothelial progenitor cells (EPCs) have reparative potential in overcoming the endothelial dysfunction and reducing cardiovascular risk. Aim: To investigate the relationship between endothelial function and EPCs in patients with AS in a cross-sectional study. Methods: Circulating EPCs (CD34+/CD133+) were isolated and quantified from peripheral blood samples of AS (n23) and healthy controls (n=20) matched for age and sex. Endothelium-depended vascular function, i.e. flow-mediated dilation (FMD), was assessed for all subjects. Disease activity was evaluated using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Functional ability was monitored using Bath Ankylosing Spondylitis Functional Index (BASFI). All subjects were free of any other known traditional CV risk factors. Results: AS patients had depleted level of circulating %EPCs (0.028 ± 0.001% versus 0.045 ± 0.011%, P <0.001) and reduced FMD% (6.77 ± 2.15 versus 10.06 ± 0.55, P <0.001) than healthy controls. Circulating EPC population significantly positively correlated with FMD% (r 0.538, P = 0.008). Levels of CD34+/CD133+ putative cells showed a significant inverse correlation with disease duration (P = 0.01), BASDAI (P = 0.04), ESR (P = 0.002) and CRP (P = 0.007). Conclusion: AS patients, free of any other known CV risk factors, demonstrated depleted levels of EPCs and reduced endothelial function. These alterations may cause further deterioration of endothelial function in AS patients. EPC would possibly serve as a novel therapeutic target for preventing cardiovascular risk in AS.
No takes yet. Share an insight, caveat, or question.
Krishan et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: